Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the National Medical Products Administration for Ademetionine 1,4-Butanedisulfonate for Injection, with a specification of 0.5 grams. The registration classification is chemical drug category 4, and it is deemed to have passed the generic drug quality and efficacy consistency evaluation. The drug is indicated for intrahepatic cholestasis before and due to liver cirrhosis, as well as intrahepatic cholestasis during pregnancy. Data from Menet shows that from 2023 to 2025, sales of this drug in domestic public medical institutions were 880 million yuan, 840 million yuan, and 980 million yuan respectively. The company stated that this approval will further enrich its product pipeline and enhance its market competitiveness in the field of digestive system treatment. However, drug sales are affected by national policies, market conditions, and other factors, and the impact on the company's performance after launch is uncertain.
Shandong Jincheng Pharmaceutical and Chemical Co LtdSubsidiary's drug approval enriches product pipeline and enhances competitiveness in digestive system treatment.
Directly obtained drug registration certificate for Ademetionine 1,4-Butanedisulfonate for Injection.